GLP-1 Weight Loss with Autoimmune Expertise
At One Rheumatology, weight management goes beyond weight loss - helping reduce inflammation, improve mobility, and support autoimmune health.
GLP-1 Weight Loss: Essential Program
275$Every monthLower-Dose GLP-1 Weight-Loss Program (2.5 - 7.5 mg). A physician-led program for patients starting or maintaining lower doses, with personalized guidance to support steady, sustainable weight loss.Valid for 12 months- 4-week supply of compounded tirzepatide (2.5 mg–7.5 mg)
- Physician-prescribed and clinically monitored
- First dose and injection training available in clinic
GLP-1 Weight Loss: Advanced Program
425$Every monthHigher-Dose GLP-1 Weight-Loss Program (10-15 mg). A physician-led program for patients progressing to higher doses, with personalized guidance to support steady, sustainable weight loss.Valid for 12 months- 4-week supply of compounded tirzepatide (10 mg– 15 mg)
- Physician-prescribed and clinically monitored
Lily Direct Zepbound Membership
99$Every monthAuthentic tirzepatide from Eli Lilly. Medication cost paid directly to Lilly. Prescription and care managed through One Rheumatology at 99 dollars monthly.Valid for 12 months- FDA-approved tirzepatide manufactured by Eli Lilly
- $99/Month Clinical Management by One Rheumatology
- LillyDirect® using eligible insurance coverage or self pay
Important: Membership enrollment does not guarantee treatment. Your application and medical history will be reviewed by a One Rheumatology provider to determine if tirzepatide is appropriate for you prior to arranging for first shipment/ in-office dose.
Dr. Clifford Stermer served as a principal investigator in Eli Lilly’s landmark TOGETHER clinical trials evaluating Taltz® (ixekizumab) and Zepbound® (tirzepatide) in patients with psoriatic disease and obesity. These studies demonstrated that treating excess weight alongside autoimmune disease led to significantly better outcomes than biologic therapy alone, with greater improvements in disease activity, higher rates of skin clearance, and meaningful weight loss. (Lilly Investor Relations)
Research continues to show that obesity can contribute to chronic inflammation and reduce response to biologic therapies. For patients with a BMI of 30 kg/m² or greater, or 27 kg/m² with a weight-related medical condition, medically supervised tirzepatide may be an important part of a comprehensive treatment plan. (Lilly Investor Relations)
Our physician-led membership program combines personalized medical supervision, compounded tirzepatide, ongoing dose optimization, nutrition guidance, and expert care from a team dedicated to autoimmune medicine - helping you achieve healthier weight, lower inflammation, and better long-term outcomes.
